Penn LDI Launches $2.5 Million CKD Research Initiative
A Gift from Monogram Health Supports a Three-Year Program Focused on Improving Care and Addressing Racial Inequities
The University of Pennsylvania’s Leonard Davis Institute of Health Economics (LDI) is launching a new initiative to support research on improving the management of chronic kidney disease (CKD), with a particular focus on addressing disparities including structural barriers and racial inequities. The three-year research initiative is made possible by a $2.5 million gift from Monogram Health.
Called the Penn LDI Research Initiative on Improving Management of Chronic Kidney Disease, the effort will involve Penn LDI Senior Fellows and research teams that have been at the forefront of identifying drivers of CKD progression and barriers to the use of home dialysis therapies, transplantation, and palliative care.
Penn LDI is the University’s hub of health services research with more than 500 Senior and Associate Fellows involved in interdisciplinary health care research, a number of whom are focused on addressing barriers to evidence-based treatment for kidney disorders. Monogram Health is a Tennessee-based company focused on helping providers better manage patients with CKD and end-stage renal disease (ESRD).
Important New Evidence
“We are excited about this pairing and the opportunity and the public-private partnership to help advance research in this area,” said LDI Executive Director Rachel M. Werner, MD, PhD. “LDI’s expertise and academic authority on innovating and improving health care delivery and Monogram Health’s commitment to measurably improving outcomes for individuals living with CKD complement each other. This research initiative provides the opportunity to generate rigorous and important new evidence to advance the field through effectively identifying, managing, and improving outcomes of patients with CKD, while also reducing health inequities.” Werner is also a Professor of Health Care Management and Economics at the Wharton School.
“This commitment from Monogram Health signals a step forward in equitable health care access and innovative research, bringing meaningful resources to Penn LDI and its partnerships across the University,” says Wharton School Dean Erika James.
More than one in seven adults in the U.S., or 37 million people, are living with CKD, a condition that disproportionately affects communities of color. CKD rates are almost four times higher among Black Americans than white Americans. Many with CKD are unaware they have the condition, limiting the opportunity to manage and prevent its progression to end-stage renal disease.
More than half a million people in the U.S. annually use dialysis to replace their failing renal functions. Only about 13% of these are engaged with dialysis-at-home systems, even though at-home treatment is now recognized for providing a higher quality of life, improved care, and better outcomes.
LDI Senior Fellows’ studies have previously revealed substantial racial and ethnic disparities in survival, cardiovascular comorbidities, and function of patients with CKD. LDI Fellows also wrote the seminal paper in the Journal of the American Medical Association (JAMA) challenging the widespread use of race to adjust the estimated glomerular filtration rate (eGFR), noting the practice could lead to underdiagnosis and undertreatment of CKD in Black patients, potentially reducing access to specialty care, clinical trials, and kidney transplantation.
Urgency for Improved Access
“Over the last five years, the federal government and providers caring for patients with kidney disease have asserted the urgency of improving access to care and breaking down barriers to home dialysis and transplantation,” said LDI Senior Fellow and Initiative Director Peter Reese, MD, PhD. “The White House pushed these initiatives with the Advancing American Kidney Health initiative. This partnership with Monogram is going to drive progress on these issues with high quality, pragmatic research.”
Reese is a Professor of Medicine and Epidemiology at the Perelman School of Medicine, an NIH-funded transplant nephrologist andepidemiologist, and past chair of the Ethics Committee for the United Network for Organ Sharing which oversees transplant regulation in the U.S. He noted the three areas the new Initiative’s research portfolio will focus on these three areas:
- Improving access to specialty providers because the lack of access to nephrologists is a major barrier to optimal care of CKD and management of its comorbidities, including hypertension.
- Improving the uptake of evidence-based treatment and preventing the progression of CKD because, despite a substantial knowledge base of diagnostic and therapeutic approaches for care, many individuals with CKD often do not receive evidence-based care.
- Improving the financing and delivery models for people with ESRD because care for advanced CKD patients is often fragmented, with providers working in silos that do not communicate well. There are also perverse economic incentives that prevent optimal care for the patient with in-center hemodialysis as a default pathway.
More on Health Equity
Causal Evidence From Nonparametric Bounds
Q&A on Patient-Reported Racism and Emergency Department Care
Telemedicine Cannot Smooth Care Transitions for all Patients
Selects a Team Study from the COVID Watch Program Led by LDI Senior Fellows
Balancing the Perceived Benefits and Risks of Research Participation is No Easy Task for Cancer Patients
Toward A Better Understanding of Patients Perspectives